SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Allianz SE (ALIZY) trades at a trailing P/E of 16.4, forward P/E of 12.7. Trailing earnings yield is 6.10%, forward earnings yield 7.87%. PEG 0.02 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (85/100, Pass) — P/E is below market average (16.4); PEG ≤ 1.0 — Peter Lynch undervalued (0.02); earnings yield beats bond yields (6.10%).
- Forward P/E 12.7 (down from trailing 16.4) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.02 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 6.10% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 7.87% as earnings recover.
Overall SharesGrow Score: 76/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
85/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ALIZY
Valuation Multiples
P/E (TTM)16.4
Forward P/E12.7
PEG Ratio0.02
Forward PEG0.44
P/B Ratio0.00
P/S Ratio1.24
EV/EBITDA0.0
Per Share Data
EPS (TTM)$2.77
Forward EPS (Est.)$3.57
Book Value / Share$0.00
Revenue / Share$36.59
FCF / Share$0.00
Yields & Fair Value
Earnings Yield6.10%
Forward Earnings Yield7.87%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$1.52 |
$107.51B |
$6.88B |
6.4% |
| 2017 |
$1.52 |
$107.43B |
$6.8B |
6.3% |
| 2018 |
$1.74 |
$102.98B |
$7.46B |
7.2% |
| 2019 |
$1.88 |
$113B |
$7.91B |
7% |
| 2020 |
$1.63 |
$112.24B |
$6.81B |
6.1% |
| 2021 |
$1.58 |
$118.91B |
$6.61B |
5.6% |
| 2022 |
$1.59 |
$114.3B |
$6.42B |
5.6% |
| 2023 |
$2.12 |
$124.64B |
$8.54B |
6.9% |
| 2024 |
$0.25 |
$139.84B |
$9.93B |
7.1% |
| 2025 |
$2.77 |
$137.81B |
$10.78B |
7.8% |
